Predict your next investment

SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
softway-medical.fr

See what CB Insights has to offer

Stage

Growth Equity | Alive

About Softway Medical

Provider of medical software. The company provides medical software for hospital management and private practices, and for use in X-rays.

Softway Medical Headquarter Location

445 rue Andre Ampere

Aix-en-Provence, 13799,

France

33 4 88 71 13 00

Latest Softway Medical News

The Top 25 Healthcare Technology CEOs Of Europe For 2021

Jul 27, 2021

. As the coronavirus continues to impact populations in various parts of the world, a brighter light has shone on the critical importance of healthcare innovation across biotechnology, medical devices, software, and consumer products, among other areas. European healthcare technology CEOs have demonstrated impressive leadership over the past year while adapting to increased demand as well as shifting priorities in the market. Despite the myriad of challenges presented in the current environment, this year’s awardees have led their organizations ably. And through their expert leadership, their companies have continued to produce innovative solutions for some of the world’s most complex health problems. Nominees were evaluated based on their breadth and depth of experience, consistently high organizational performance, contributions to the industry, and reputation among peers. Each of the CEOs recognized has had profound impact on the companies they lead; they have made strategic decisions to drive operational expansion, augment research capabilities, and launch new products and services. Please join us in congratulating each of this year’s Top 25 Healthcare Technology CEOs of Europe for 2021. UCB Jean-Christophe Tellier brings over 30 years of experience in the biopharmaceutical industry to his position as the CEO of UCB. UCB is a Belgium-based biopharmaceutical and specialty chemical company that specializes in diseases of the central nervous system and immunology. The company was founded in 1928 and has brought several innovative drugs to patients across the world, including Cimzia, Vimpat, and Briviact. Tellier joined UCB in 2011 as Executive VP of European Operations and was appointed as CEO in 2015. Tellier is currently a member of the UCB Board of Directors, President of the Board of the European Federation of Pharmaceutical Associations, a member of the Board of Pharmaceutical Research and Manufacturers of America, and a member of the Board of Walloon Excellence in Life Sciences and Biotechnology. Previously, he was the President and GM of North American Operations at Ipsen, where he strengthened Ipsen’s specialty care business in North America in the areas of endocrinology and neurology. Tellier is trained as a medical doctor specializing in rheumatology and is known for his patient-centric approach and passion for science. Takeda Pharmaceutical Company Christophe Weber is the President, Chief Executive Officer, and Representative Director of Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The Japanese research and development company was established in 1781 and focuses on oncology, rare diseases, neurosciences, and gastroenterology. Most recently, the company opened a new research and development cell therapy manufacturing facility in Boston, Massachusetts. Weber joined the company in April 2014 as Chief Operating Officer and was appointed as President and Representative Director by June that same year. In 2015, he was named CEO. In his current position, Weber has focused his skills on Takeda’s research and development transformation and globalization, and on building a diverse and inclusive workforce and strengthening the company’s ethical values and corporate governance. Before joining Takeda, Weber was at GlaxoSmithKline for 20 years, where he held various leadership roles. Weber is also a member of The Business Council, the World Economic Forum’s International Business Council, the Singapore Economic Development Board’s International Advisory Council, the New York Stock Exchange’s NYSE Board Advisory Council, and the MIT CEO Advisory Board. Zentiva Nick Haggar has been leading Zentiva into a phase of unprecedented growth as CEO since February of 2019. Zentiva is a producer of high-quality affordable medicines serving patients across Europe and beyond. They strive to be the champion of branded and generic medicines in Europe to better support daily healthcare needs, with a belief that healthcare should be a right, not a privilege. They work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide everyday solutions. The company recently made steps in growing their Oncology medicines portfolio with the collaborative launch of ALYMSYS® in March 2021. In addition to his role with Zentiva, Haggar has been the CEO of Insud Pharma since 2016, where they lead the Chemo Global Business. Prior to his current positions, he was the Head of West Europe, Middle East and Africa for Global Respiratory and Novaris Access to Medicines for Sandoz International GmbH. He served as Member of the Sandoz Executive Committee and a Co-Chair to the Novartis Access to Medicines Committee. Haggar earned an Executive MBA from Cranfield University - Cranfield School of Management. Dupont Edward Breen is the CEO at DuPont, a sustainable solutions provider for agriculture, electronics, communications, construction, transportation, apparel, and pharmaceutical markets. Established in 1802, DuPont has been innovating and reinventing technology-driven solutions for over 200 years. Breen is tasked with overseeing the strategic direction of the company and execution of DuPont’s priorities for value creation as it unlocks the full potential of its distinctive capabilities, innovative portfolio, application expertise, and deep customer relationships. He has driven significant performance improvements across DuPont’s businesses, negotiated one of the most transformative mergers in the industry to create DowDuPont, and launched three independent companies. Breen has served as the Executive Chairman of Dupont since 2019, and previously was the Chief Executive Officer of DowDuPont. Preceding the merger of DuPont and The Dow Chemical Company he was the Chairman and CEO of DuPont. Prior to DuPont, Breen served as the CEO and Chairman of Tyco International, and the President and CEO of Motorola. He was also the Chairman, President, and CEO of General Instrument Corporation. Along with his role at DuPont, Breen is currently a Director of Comcast Corporation and a member of the advisory board of New Mountain Capital. Amplifon Enrico Vita is the CEO and GM of Amplifon, a global leader in the hearing care retail market. The Italian company was founded in 1950, works with 14,000 people worldwide, and has grown its operations to France, Spain, Portugal, Switzerland, Austria, Holland, the U.S., Hungary, and Egypt. Vita joined Amplifon in 2014 as the Executive VP for EMEA before becoming COO, where he was responsible for the corporate functions of marketing, IT, and supply chain management. In 2015, he succeeded Franco Moscetti as CEO. Vita also currently serves on the Board of Ariston Thermo Spa as the Director. In 2019, he led Amplifon through its acquisition of Attune Hearing, Australia’s largest independent audiology operator. Before his role at Amplifon, Vita spent over 20 years at Indesit Company (formerly Merloni Elettrodomestici). He joined in 1995 and held several roles of varying seniority during his tenure, including Group Supply Chain Officer, Managing Director of U.K. and Ireland, and eventually COO. Vita holds a Master of Engineering degree in Mechanical Engineering from the Università Politecnica delle Marche. Novozymes Ester Baiget is the President and Chief Executive Officer of Novozymes, a world leader in bioinnovation. Established in 2000, the Danish company focuses on the research, development, and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. Baiget joined Novozymes in February 2020, succeeding Peder Holk Nielsen. She is an experienced international leader, driving transformational change and profitable growth. Previously, Baiget was the Business President for Dow’s industrial solutions business unit and a member of the Executive Leadership Team. Since joining Dow in 1995 as an engineer in Tarragona, Spain she has held various manufacturing, technical, commercial, and strategic roles. During her 25-year tenure at Dow, Baiget implemented a clear growth, innovation, and operational strategy that produced strong financial results. Now at Novozymes, Baiget is known for her strong commercial credentials, technical expertise, and engaging leadership style. Baiget has a passion for science and inspires colleagues and future generations through her role as a STEM ambassador and as an active advocate of the Women’s Innovation Network. Arjo Joacim Lindoff is the President and CEO at Arjo, a leading provider of solutions aimed at reducing mobility and age-related health challenges. Headquartered in Malmö, Sweden, the company was founded in 1957 and has since grown into a global supplier of medical devices, services, and solutions that span patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism prevention, and diagnostics. Lindoff became the company’s CEO in 2017 following Arjo’s split with Getinge, which acquired the company in 1995. That same year, under Lindoff’s leadership, Arjo prepared its public listing, which they achieved on time at the end of 2017. Notably, the company has been pivotal in meeting the high demand for hospital beds during the COVID-19 pandemic. Before the spin-off, Lindoff was at Getinge for almost nine years, where he was President of Nordic Sales and Services, Executive VP of Getinge Infection Control, Executive VP of Surgical Workflows, and acting CEO of Getinge Group. In 2010, Lindoff was appointed Chairman of Swedish Medtech, the Stockholm Medical Technology Industry Association, a role he served in until 2014. Lindoff received a Bachelor of Science degree in Economics from Lund University. eCential Robotics As MD and CEO, Laurence Chabanas and Stéphane Lavallée make a strong management duo at the head of eCential Robotics. Created in 2009 by Lavallée, eCential Robotics' goal is to reinforce the safety and accuracy of surgical procedures. With the objective of enabling surgeons and their teams to practice in a reliable and simple environment, eCential Robotics has focused its development on a unique and innovative concept: focusing surgical workflows on the essential to make robotic-assisted bone surgery simple enough in routine that it becomes a standard of care. In June 2021, they unveiled a surgical robotic arm that will enhance eCential Robotics’ unified universal platform combining 2D/3D robotic imaging, navigation, and robotic surgery. Chabanas has over 20 years of experience in the robotic surgery industry. She has developed computer assistance systems for orthopedics, including robotic and software applications, marketed today by J&J or Corin. She joined eCential Robotics in 2019 as Chief Strategy Officer and Managing Director. Lavallée has developed the first image-guided robotic system used in clinical routine at Grenoble Alpes University Hospital. He founded different companies in the robotic surgery area focusing on one technology for one indication, most of which have been acquired by global groups. To structure these innovations, he has also created an incubator and an accelerator dedicated to surgical robotics in Grenoble. Dedalus Group Andrea Fiumicelli has been Chief Executive Officer and a member of the Executive Committee of Dedalus Group since mid-2020. Dedalus Group is a leading international industrial group in healthcare software that represents the highest level of experience and functional completeness in IT systems to support clinical processes. They aim to support healthcare organizations, their professionals and the people thanks to an innovative approach on complete and process-oriented solutions with the focus at clinical collaboration. Fiumicelli has a long history in the healthcare software business with over 20 years of success. Prior to his role at Dedalus Group, Fiumicelli was the Vice President and General Manager of DXC Technology following the merger of Computer Science Corporation and the Enterprise Services business of Hewlett Packard Enterprise Services. Before DXC Technology, Fiumicelli led iSOFT as CEO and COO helping restructure the healthcare software business and improved the customer’s experience, restored profitability, accelerated innovation and streamlined a robust and complex product set. Fiumicelli graduated from the University of Genova with a doctorate degree in Theoretical Physics. LivaNova Damien McDonald is the CEO of LivaNova, a London, England-based medical device manufacturer developing devices used for cardiac surgery and neuromodulation. The company was founded in 1987 and is committed to improving patient care across the world through innovation. McDonald was previously the company’s COO and rose to the position of CEO in 2017. He joined LivaNova from Danaher Corporation where he was the Group Executive and Corporate VP, leading a $1.5 billion group of dental consumables companies. McDonald is currently a non-executive Director of the regenerative medicine company Avita Medical. McDonald has a strong track record of leading growth and development. He formerly served as the group president of Kerr, where he oversaw a team focused on growing a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Before this, McDonald led Zimmer Biomet’s spine division where he led a strong executive team that created a significant growth trajectory for the business. McDonald earned a Master of Business Administration degree at the Institute for Management Development in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K.   Pears Health Cyber Vladimir Finsterle is the owner and CEO of Pears Health Cyber headquartered in Prague. At Pears Health Cyber, their teams are dedicated to patient’s happiness, employee success and new opportunities that allow constant innovation and improvements to cooperation in healthcare. With a focus in selling pharmaceutical and related products, Pears Health Cyber works to invent strategies and products that work with modern media and technologies. They were the first online pharmacy store in Czech Republic and Slovakia. Finsterle started his career in 1989 in immunology at IKEM in Prague before taking an opportunity to help build a pharmaceutical company called CILAG. Prior to joining Pears Health Cyber in 1999, Finsterle spent 9 years in Marketing and Sales at Johnson & Johnson. He graduated from the Faculty of Pharmacy of Charles University in Hradec Králové. Hartmann Group Britta Fuenfstueck is the CEO at Hartmann Group, a leading global provider of medical and hygiene products. Founded in 1818, the Hartmann Group has been driving healthcare forward with innovations and achievements for over 200 years. The company is known for producing high-performance products in the areas of advanced and traditional wound management, incontinence management, and sports medicine. Since becoming Hartmann Group’s CEO in 2018, Fuenfstueck has been charged with taking the company into its next stage. With over 20 years of chief executive and healthcare industry experience, Fuenfstueck values people and culture above all else in a company, citing this as her core reason for joining Hartmann Group. Before joining Hartmann Group, Fuenfstueck was an Executive Committee Member at Clariant, a leader in specialty chemicals. In this role, she was responsible for the plastics and coatings business, as well as several corporate functions. Previously, she also worked as a Manager of Siemens Healthineers where she was tasked with portfolio planning, marketing, business development, and product management. She also headed the company's strategy as well as its mergers and acquisitions. Fuenfstueck has a Master of Science degree in Engineering Physics from Johannes Kepler Universität Linz. LifeBee Teresa Minero is the Founder and the CEO of LifeBee, a business and digital consulting firm supporting Life Science companies on their path towards digitalization, operational excellence and compliance. With 18 years of operation, headquarter in Italy and a branch in Switzerland, LifeBee is staffed with over 50 professionals, with 700+ successful projects completed with more than 70 Italian and international clients, exclusively within the Life Sciences. Minero has more than 30 years of experience in managing international consulting and digital innovation projects for production, logistics, quality, regulatory and R&D, and in managing startups and business divisions for international consulting groups. More than 25 years have been spent within Life Sciences. Prior to joining LifeBee, Minero was the Consulting & System Integration Business Manager with Atos and before that a Project Manager for 13 years at SESAM. Today she is currently part of the International Board of Directors, the European Leadership Team, and the Steering Committee Pharma 4.0™ Global Special Interest Group. She has been Lecturer and Chairman at many Conferences and author of several articles on Digitalizing Life Sciences and Pharma 4.0™. Evotec Dr. Werner Lanthaler is the CEO of Evotec, a drug discovery alliance and development partnership company. The German company was founded in 1993 and has rapidly developed innovative approaches to products alongside leading pharmaceutical and biotech firms, venture capitalists, academics, and patient advocacy groups. Dr. Lanthaler joined the company in 2009 when he was tapped to take the company to its next level of success. Dr. Lanthaler has focused the company on supporting innovation and collaborating with biotech and pharma companies. With a proven track record in development, and a strong sense for the creation of shareholder value, Dr. Lanthaler’s expertise positions him as a valued industry thought leader. Previously, Dr. Lanthaler served as the CFO of Intercell AG in Austria. At Intercell, he led business development as well as marketing and sales and played a pivotal role in the company’s major milestones. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. He holds a doctorate in Economics from Vienna University and an MBA degree from Harvard University. Brainlab Stefan Vilsmeier is the Founder and CEO of Brainlab, a company that develops software and hardware devices that create and enhance data to improve critical surgeries, radiosurgery treatments, and operating room efficiency. Founded in 1989, Brainlab started with customers throughout Asia, North America, and South Africa. Originally focused on software solutions for medical treatments that are more precise, less invasive, and less expensive than traditional methods, Brainlab has extended its value proposition under Vilsmeier’s leadership to bring a new level of integration and patient care to entire medical centers through state-of-the-art access and management of digital medical information. Vilsmeier began his career as a self-taught computer programmer and wrote a bestselling book on 3D graphics at age 17. He went on to found Brainlab during his first semester at the Technical University of Munich using the proceeds from his book. Vilsmeier has received many awards throughout his career, including a special award for innovative leadership methods and marketing concepts at the Bavarian Innovation Awards in 2000. He was also appointed to the advisory board for subject matter experts of the German Federal Ministry of Economic Affairs and Energy. Bone Therapeutics Miguel Forte is CEO of Bone Therapeutics, where he is currently leading the company in its transformation to a prominent position developing engineered MSC derived cell and gene therapy for multiple indications. Miguel is also part of the Board of Directors for the Alliance for Regenerative Medicine and Essenscia-Wallonie. He is additionally visiting Professor at the Lisbon University in Portugal. Before joining Bone Therapeutics in 2020, Forte was CEO of Zelluna Immunotherapy from 2017 to end of 2019, where he oversaw the evolution of the company from a start-up to a pre-clinical stage allogeneic cell therapy developer for solid tumors. Also, Forte was the Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy between 2016 and 2020. From 2010 to 2017 Forte was CMO and COO of TxCell, establishing and leading a professional translational approach in CGT product development for autoimmune diseases and transplantation. Forte holds an M.D. from the Faculty of Medicine of the University of Lisbon, a Ph.D. in Immunology from the University of Birmingham, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies from the Stockholm School of Economics. 3Shape Jakob Just-Bomholt is the CEO of 3Shape, a company that aims to change the dental care industry with innovative technology-based solutions. Founded in 2000, the Denmark company creates 3D scanners and CAD/CAM software solutions to improve patient care for dental and audiology professionals worldwide. Just-Bomholt took on the role of CEO in August 2020, leaving his position as Executive VP of Falck A/S, a global emergency and healthcare company. With a proven leadership track record and a wide scope of business experience, Just-Bomholt continues to foster 3Shape’s consistent growth, including a strong focus on leading with innovation. In his previous role at Falck, Just-Bomholt headed the company's Emergency Service Division. Before this, he was the CEO of APM Terminals. Just-Bomholt also spent 20 years at A.P. Moller-Maersk in roles of increasing seniority, including Managing Director and GM. In 2011, he successfully started a new business at A.P. Moller-Maersk, the Seago Line, of which he was the CEO until 2015. Now at 3Shape, his goal is to develop the company together with the 3Shape team to deliver value to the company’s customers and partners for better patient care. EUSA Pharma Dr. Carten Thiel was previously head of EUSA Pharma’s European and global marketing team, and has 27 years of experience in a variety of international roles in the pharmaceutical industry. He previously served as chief commercial officer at Alexion Pharmaceuticals and was an executive at Amgen for 14 years, holding multiple roles of increasing commercial responsibility, including head of the firm’s European business. He also holds a PhD in Molecular Biology and Biochemistry. Ypsomed Holding Simon Michel is the CEO of Ypsomed Holding, a leading developer and manufacturer of injection and infusion systems for self-medication. Since its establishment in 2003, the Switzerland company has been renowned for its specialty in diabetes research and has grown its operations across the world. It has become the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors, and infusion systems to administer liquid drugs. Michel joined the company in 2006 as the Business Development Manager of Diabetes Care, before going on to become VP of Infusion Business and Senior VP of Marketing and Sales. He was appointed as CEO in 2014, where he oversees the strategic growth of the company. Before Ypsomed, Michel was the Corporate Program Manager and Segment Manager of New Businesses at Orange Communications. Previously, he was also a Business Analyst at Arthur D. Little and a Project Manager at Disetronic Medical Systems. In March 2017, Michel was also elected to the Cantonal Council of the Canton of Solothurn. Michel received a Master of Media and Communications Management degree from the University of St. Gallen. Oxford Nanopore Dr. Gordon Sanghera is the Co-Founder and CEO of Oxford Nanopore Technologies, a developer of nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins. The company was founded in 2005, and its electronic-based DNA and RNA sequencing technology is utilized in more than 80 countries. Dr. Sanghera has over 20 years of experience in the design, development, and global launch of disruptive platform sensor technologies. At Oxford Nanopore Technologies, he has overseen the launch of numerous innovative tools used by researchers in medicine, epidemiology, environmental science, forensics, and genomics. Notably, he has also developed and validated production processes to meet the regulatory requirements for the U.S. and Europe. Previously, Dr. Sanghera was at MediSense, an Oxford spin-out that delivered a new generation of glucose technology to the market. In his time there, he was pivotal to the launch of several generations of blood glucose bio-electronic systems for consumer and hospital medical markets. Following the acquisition of MediSense by Abbott Laboratories, Dr. Sanghera served as the VP of Worldwide Marketing, Research Director, and Manufacturing Process Development Director. He earned his PhD from Cardiff University. Biotage Tomas Blomquist is the President and CEO of Biotage, a provider of efficient separation technologies and high-quality solutions for analytical chemistry. Founded in 1969, the Scandinavian global life science company has clients that span public authorities, academic institutions, pharmaceutical, and food industries, among others. In 2019, Blomquist was appointed as the CEO of Biotage and brought to the table his expertise in corporate strategy, people development, business model innovation, internationalization, organizational design, and commercialization. With more than 25 years of experience, Blomquist is a veteran in the healthcare industry and has a specialization in the fields of diagnostics and medtech. Previously, he was the VP of EMEA Cardiometabolic at Abbott, and at Alere, he was the Managing Director of Nordic and Western Europe. He was also the GM of Northern and Eastern Europe, VP, and then President at Analyticon. Before Analyticon, Blomquist spent eight years at Johnson & Johnson as the Nordic Business Unit Director and at Roche as Sales Manager of Patient Care in Sweden. In these roles, Blomquist fostered high performance and growth through direct and indirect sales channels in more than 100 countries. Softway Medical Patrice Taisson has been the Chief Executive Officer of Softway Medical for nearly 20 years, and today, the company serves over 1,100 health facilities. The company offers technology for ICU, acute care, surgery, oncology, pediatrics, mental health, and elderly care centers. Its solutions include a hospital management platform, administration management functionality, diagnostics, pharmacist solutions, and follow-up treatment management. The company has been committed to improving the performance of care for more than 25 years, and it aims to place the healthcare professional at the heart of the healthcare system by providing tools for optimizing the performance of their profession, for the benefit of the patient. Taisson started his career as Administrative and Financial Director with a high-tech cabling manufacturer. Taisson was then the Chief Financial Officer, and subsequently Chairman of the Management Board for Waid, before joining Softway Medical in 2003. In his role as CEO at Softway, he brings together activities in the radiology, hospital, and clinical information system markets. He graduated from the Universite de Nice-Sophia Antipolis. Evaluate, Ltd. Deborah Kobewka has led Evaluate since March of 2019. Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry, transforming their confidence in strategic decisions through a better understanding of the past, present, and future of the global pharmaceutical market. Kobewka has 30 years of experience in the healthcare, pharmaceutical, and information industries. Kobewka added even greater depth to Evaluate’s portfolio with the launch of Evaluate Omnium, a product offering that leverages machine learning and Evaluate’s extensive data archive to fill critical information gaps in the early-stage clinical pipeline. Kobewka joined Evaluate from a government role, having served as the Managing Director of Healthcare U.K., Life Sciences and Bio-Economy at the U.K.’s Department for International Trade. Before that role, Kobewka held senior operational and corporate roles in government and the private sector throughout the U.K., Europe, and Asia. Kobewka emphasizes a dynamic leadership style, which has helped her team remain successful during the massive changes due to COVID-19, as staff had to switch to work-from-home operations. Having already strengthened the company’s portfolio and improved R&D productivity, Kobewka looks forward to adding to the exciting developments of the last few years. Tristel Global Paul Swinney is the Founder and Chief Executive Officer at Tristel Global, a market-leading infection control products specialist. Swinney has been the Chief Executive and a shareholder in the Cambridgeshire-based company since its inception in 1993. Now, 27 years later, Tristel’s instrument disinfectants are used in 60% of all hospitals in the country, and its cutting edge product lines, which include surface and skin disinfectant solutions, foams, and wipes have taken on competitors like Johnson & Johnson. During the COVID-19 pandemic, Tristel has seen an enormous increase in disinfectant sales, and the company expects turnover to rise this year by 21% to reach £31.6 million, compared to £26.2 million in 2019. Swinney left behind an illustrious career in banking to jump into the medtech sector. Swinney started his career with Brown, Shipley & Co in 1980. He worked for the European banking operations of Norwest Bank Minneapolis and Maryland National Bank, before joining OSI Finance, a specialist in shipping finance in 1987. Now at Tristel, Swinney is known for his rapid and assured decision-making and for having an engaging, reflective, considerate, and no-nonsense leadership style. Centogene Andrin Oswald is the CEO of Centogene, joining the company in late 2020. Centogene is one of the worldwide leaders in the genetics field, transforming genetic data into medical decisions. They focus exclusively on providing the highest quality, patient-centered service, verified by several international accreditations. Centogene’s medical expertise is based on cutting-edge technologies including exome/genome sequencing and innovative biomarkers. Oswald has had decades of experience within the healthcare industry working towards progress and change for patients and physicians. In addition to his role at Centogene, Oswald serves on the Board of Directors for Univercells where they make biologics available to all. He has previously served as a Member of the Board of Directors and on the Investment Committee for Global Health Investment Corporation. Upon graduating Oswald moved on to roles at Red Cross, Novartis, GSK, Swiss Federal Administration and Global Health Innovative Technology. One of his most notable roles was as Director of Life Science Industry Engagement and Partnership at the Bill & Melinda Gates Foundation where he led the foundation’s engagement with the industry and supported teams towards developing and advancing their R&D and delivery technologies. Oswald graduated from the University of Geneva with a Doctor of Medicine.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.